Myasthenia gravis
RSS feedConditioned mesenchymal cells to alleviate Myasthenia Gravis
Mesenchymal stromal cells (MSCs) are promising tools for the treatment of autoimmune and inflammatory diseases. These multipotent stromal cells possess innate immunomodulatory properties that can be significantly enhanced by co-culture with peripheral blood mononuclear cells (PBMCs). Researchers at the Institute’s Center of Research in Myology and their colleagues studied the mechanisms underlying the conditioning of … [Read more]
A pharmacovigilance study on the use of efgartigimod in myasthenia gravis in the United States
Efgartigimod is one of the new molecules used in refractory forms of myasthenia gravis. Chinese researchers have reviewed the side effects recorded in the Food and Drug Administration (FDA) pharmacovigilance database, which is freely accessible in the United States: the study covered the period from the first quarter of 2022 to the fourth quarter of … [Read more]
Encouraging results from the ventilatory weaning protocol during myasthenic crises
French clinicians involved in weaning myasthenic patients undergoing decompensation (myasthenic crisis) report the results of the WEAN Safe protocol applied to a single-center cohort (Paris, SalpĂȘtriĂšre): of the 698 admissions to intensive care for this reason, only the records of 81 patients covering the period 2008-2023 were selected for the study, the median age of … [Read more]
The importance of measuring autoantibodies directed against rituximab in myasthenia gravis
Neurologists in Nice report on their experience in the long-term treatment of autoimmune myasthenia gravis, particularly in the use of a monoclonal anti-CD20 antibody (rituximab or RTX): data from 101 patients with myasthenia gravis treated with RTX as a first- or second-line therapy were included in a retrospective study. Among them, 34 developed autoantibodies directed … [Read more]
A new international registry for patients with myasthenia gravis
MGBase is a registry created in 2021 to compile online data on myasthenic patients worldwide: it is directly inspired by a registry developed for multiple sclerosis (MSBase), which collected data from 107,000 patients. In three years, MGBase has recorded the clinical and immunological data of 565 patients with myasthenia gravis included by 16 centres operating … [Read more]
The Danish experience with myasthenia gravis
Danish researchers report the results of a large epidemiological study on mortality observed in myasthenia gravis between 1985 and 2020: the information was drawn from existing health data warehouses in Denmark, mortality figures were defined according to the date of occurrence of the event (within one year [short term], or between 1 and 5 years … [Read more]
Antibodies to MuSK CRD are pathogenic in a mouse model of myasthenia gravis
Myasthenia gravis (MG) is caused by autoantibodies directed mainly against the acetylcholine receptor (AChR) or the MuSK receptor tyrosine kinase located at the neuromuscular junction. Several studies have reported immunoreactivity against the Frizzled cysteine-rich domain (CRD) of MuSK in patients, although the pathogenicity of the antibodies involved remains unknown. A collaboration involving several teams from … [Read more]
Towards European standardisation of registers and digital tools for myasthenia gravis
European experts met in conclave at the European Neuromuscular Center (ENMC) to define standards for the identification and management of patients with autoimmune myasthenia gravis. The ten patient registries currently in use or under development were analysed and compared, with expectations and objectives varying depending on the point of view (that of clinicians, patient associations, … [Read more]
The risk of false positivity of RACh autoantibodies persists
Italian biologists have looked retrospectively at the risk of obtaining âfalse positiveâ autoantibody results when investigating patients suspected of having myasthenia gravis, the study was limited solely to autoantibodies directed against the acetylcholine receptor (anti-RACh) of the 4,795 tests carried out over the last 20 years and revisited for the purpose, 50 true âfalse-positivesâ were … [Read more]
Tolerance of efgartimod in myasthenia gravis
Chinese researchers have studied the adverse reactions observed when efgartigimod, a new-generation immunosuppressant used, among other indications, in refractory autoimmune myasthenia, is administered: their work is based on pharmacovigilance data contained in the American database managed by the FDA (Food and Drug Administration), which is freely accessible and reports all types of adverse events linked … [Read more]
